Innoviva (INVA) Expected to Announce Earnings on Wednesday

Innoviva (NASDAQ:INVA) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.34 per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Innoviva Trading Up 5.1%

Shares of INVA stock opened at $23.85 on Wednesday. Innoviva has a 12-month low of $16.52 and a 12-month high of $23.91. The company has a market capitalization of $1.78 billion, a PE ratio of 17.41 and a beta of 0.44. The firm has a 50 day moving average price of $20.35 and a two-hundred day moving average price of $19.83. The company has a quick ratio of 13.33, a current ratio of 14.12 and a debt-to-equity ratio of 0.25.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on INVA shares. Cantor Fitzgerald upped their target price on Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a research report on Monday, December 29th. BTIG Research began coverage on shares of Innoviva in a report on Tuesday. They issued a “buy” rating and a $35.00 target price on the stock. Zacks Research downgraded shares of Innoviva from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Finally, HC Wainwright increased their price target on shares of Innoviva from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.17.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its position in Innoviva by 297.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,795 shares during the period. Danske Bank A S bought a new stake in shares of Innoviva during the third quarter worth about $55,000. Lazard Asset Management LLC acquired a new stake in shares of Innoviva in the 2nd quarter worth about $92,000. Ensign Peak Advisors Inc acquired a new stake in shares of Innoviva in the 4th quarter worth about $115,000. Finally, Tower Research Capital LLC TRC lifted its position in Innoviva by 896.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,907 shares of the biotechnology company’s stock valued at $139,000 after acquiring an additional 6,214 shares in the last quarter. 99.12% of the stock is owned by institutional investors.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.